目的：探讨趋化素样因子超家族6（chemokine-like factor-like MARVEL transmembrane domain-containing family member 6，CMTM6）在乳腺癌组织中的表达及其与患者临床病理特征和预后的相关性。方法：选用购自芯超公司的136 例乳腺癌组织芯片，其中包括42 例配对的癌及癌旁组织，用免疫组织化学染色法检测乳腺癌及癌旁组织中CMTM6 的表达水平。用配对χ2检验比较CMTM6 在乳腺癌及癌旁组织中的表达差异，用χ2检验分析乳腺癌组织中CMTM6 表达水平与患者临床病理特征的关系，用Kaplan-Meier 及Log rank 分析CMTM6 表达水平与患者生存期的关系，拟合Cox模型评价不同指标对患者预后的影响程度。结果：CMTM6 在乳腺癌组织中的表达水平显著高于癌旁组织（P<0.01）。CMTM6 的表达与乳腺癌病理分型和HER2 阳性相关（P<0.05）。CMTM6 高表达组患者的生存期较CMTM6 低表达组显著缩短（P<0.05）。乳腺癌病理分型（HR=10.374，95%CI: 3.529~30.497，P<0.01）、TNM 分期（HR=4.599, 95%CI: 1.784~11.856 ，P<0.01）、三阴性乳腺癌（HR=3.370, 95%CI:1.055~10.761，P<0.05）和CMTM6 高表达（HR=0.195，95%CI: 0.073~0.518，P<0.01）均可作为评判乳腺癌患者预后的独立危险因素。结论：CMTM6 在乳腺癌组织中高表达，其可作为乳腺癌患者预后评估的危险因素。

Objective: To investigate the expression of chemokine-like factor-like MARVEL transmembrane domain-containing family member 6 (CMTM6) in breast cancer tissues and its correlation with clinicopathological features and prognosis of patients. Methods: A total of 136 breast cancer tissue chips (purchased from Superchip Company), including 42 pairs of matched cancer and paracancerous tissues,were used for this study. The expression level of CMTM6 in cancer and paracancerous tissues was detected by immunohistochemistry. The comparison of CMTM6 expression between breast cancer and paracancerous tissues was conducted by paired χ2 test. The relationship between CMTM6 expression in breast cancer tissues and the clinicopathological characteristics of patients was analyzed by χ2 test. Kaplan-Meier and Log rank test analyses were used to analyze the relationship between CMTM6 expression and the survival of patients, and Cox model was used to evaluate the effect of different indicators on the prognosis of patients. Results: The expression of CMTM6 in breast cancer tissues was significantly higher than that in paracancerous tissues (P<0.01). The expression of CMTM6 was correlated with pathological type of breast cancer and HER2 positivity (P<0.05). The survival time of patients in CMTM6 high expression group was significantly shorter than that of patients in CMTM6 low expression group (P<0.05). Pathological type (HR=10.374, 95%CI: 3.529-30.497, P<0.01), TNM stage (HR=4.599, 95%CI: 1.784-11.856, P<0.01), triple-negative breast cancer (HR=3.370, 95%CI: 1.055-10.761, P<0.05) and high expression of CMTM6 (HR=0.195, 95%CI: 0.073-0.518, P<0.01) were independent risk factors for prognosis of breast cancer patients. Conclusion:CMTM6 is highly expressed in breast cancer tissues, which can be used as a risk factor for prognosis evaluation of breast cancer patients.

国家重点研发计划资助项目（No. 2018YFC1313400）；国家科技支撑计划（No. 2015BAI12B12）；海外及港澳学者合作研究基金项目（No. 31729001）；国家自然科学基金资助项目（No. 31570877, No. 31570908）；江苏省重点研发计划（No. BE2018645）